ROK reports its fiscal Q2 2026 results today with options traders positioned more defensively than at almost any point in the past year, even as the stock has staged a sharp recovery.
The clearest signal going into the print is in options. The put/call ratio jumped to 1.49 on Tuesday — close to its 52-week peak of 1.50 and nearly 1.7 standard deviations above its 20-day average of 1.22. That level of hedging demand is unusual for a stock that has just rallied 19% over the past month to $435.93, suggesting some investors are bracing for the report rather than chasing the move. The rebound has been broad-based — ROK climbed almost 9% in a single session on Tuesday — but the options market has not let its guard down.
Short interest is not the story here. At 2.9% of the free float, with borrow costs running at around 0.40% and availability well within normal ranges, there is no meaningful squeeze pressure or aggressive short-side conviction. Short interest has edged up roughly 15% over the past month but remains a modest absolute level, and the ORTEX short score of 35 places ROK comfortably in the middle of the universe. The lending market is relaxed.
The analyst community has been in retreat. A cluster of firms — Barclays, Wells Fargo, Jefferies, and Baird — all trimmed price targets in late March and early April, with Jefferies going further and downgrading to Hold from Buy. That wave of caution arrived when the stock was trading well below current levels, which means today's price of $435.93 has already blown past several of those revised targets, including Barclays at $400 and Jefferies at $380. The mean consensus target now barely clears the current price at $435.33. Bulls lean on margin expansion — management has guided non-GAAP EPS to $9.20–$10.20, with segment margins expected to approach 20% on the back of over $250 million in year-on-year cost reductions. Bears point to underlying revenue pressure: reported sales fell 4% year-on-year last quarter across all three segments, and the forward guidance implies continued top-line weakness with a steep decremental margin profile around 28%.
Close peer EMR fell 1.4% on Tuesday and is down more than 4% on the week, while AME is roughly flat. ROK's near-9% single-day move stands apart from the group — a divergence that makes today's print a direct test of whether the recovery in the stock reflects genuine fundamental re-rating, or whether the market has moved too far ahead of a business still navigating a difficult demand environment.
See the live data behind this article on ORTEX.
Open ROK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
